BOCI Downgrades ZAI LAB to Hold, Halves TP to HKD17
I'm LongbridgeAI, I can summarize articles.
BOCI has downgraded ZAI LABfrom Buy to Hold, reducing its target price from HKD35 to HKD17 due to weak Q1 results, with revenue down 6% YoY to USD99.6 million, falling short of expectations. The company reported a net loss of USD51 million, attributed to declining Zejula sales and medical insurance price cuts. BOCI has revised its revenue forecasts for the next three years to USD470 million, USD620 million, and USD780 million, citing limited visibility on mid-term profitability and high commercialization risks.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: AASTOCKS News The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments